Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump
MT Newswires Live
Jun 11
Propanc Biopharma (PPCB) said Thursday it approved a share repurchase program allowing it to buy back up to $5 million of its common stock.
Under the program, Propanc Biopharma may repurchase shares from time to time in amounts, at prices and at times it deems appropriate, subject to market conditions, the company said.
Propanc said the company "is entering a transformative stage with a novel, first-in-class cancer therapy for treatment & prevention of metastatic cancer from solid tumors."
Propanc Biopharma shares were more than 250% higher in Thursday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.